GenMark Diagnostics market cap is $1.8 b, and annual revenue was $171.55 m in FY 2020

GenMark Diagnostics Gross profit (FY, 2020)67.9 M

GenMark Diagnostics Gross profit margin (FY, 2020), %39.6%

GenMark Diagnostics Net income (FY, 2020)-18.6 M

GenMark Diagnostics EBIT (FY, 2020)-11.1 M

GenMark Diagnostics Cash, 31-Dec-202040.6 M

GenMark Diagnostics EV1.8 B

GenMark Diagnostics revenue was $171.55 m in FY, 2020

USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2019 | FY, 2020 |
---|---|---|---|---|---|---|---|---|---|

## Net Income | (24.0m) | (22.1m) | (33.6m) | (38.3m) | (42.2m) | (50.6m) | (61.8m) | (47.3m) | (18.6m) |

## Depreciation and Amortization | 1.3m | 1.2m | 2.5m | 2.7m | 3.4m | 3.9m | 5.3m | 7.3m | 7.1m |

## Accounts Receivable | (420.0k) | (2.1m) | (2.4m) | (2.0m) | (2.0m) | (2.2m) | (1.6m) | (5.6m) | (4.1m) |

## Inventories | (1.7m) | (880.0k) | (1.3m) | (229.0k) | (1.3m) | (3.4m) | (10.5m) | (6.5m) | (12.5m) |

## Accounts Payable | 378.0k | 728.0k | 1.3m | 85.0k | (757.0k) | 4.1m | 2.6m | 1.5m | 5.2m |

## Cash From Operating Activities | (19.2m) | (16.2m) | (23.8m) | (29.6m) | (31.9m) | (35.6m) | (53.4m) | (34.9m) | 6.1m |

## Purchases of PP&E | (1.4m) | (3.5m) | (4.3m) | (5.7m) | (3.8m) | (7.0m) | (4.8m) | (2.1m) | (17.8m) |

## Cash From Investing Activities | (7.1m) | (2.1m) | (72.6m) | 29.4m | 19.3m | (24.1m) | (24.9m) | (2.2m) | (96.5m) |

## Long-term Borrowings | (417.0k) | (2.0m) | (766.0k) | (56.0k) | (22.0k) | (57.0k) | |||

## Cash From Financing Activities | 33.3m | 44.3m | 80.8m | 1.3m | 11.1m | 40.4m | 89.1m | 45.2m | 87.6m |

## Net Change in Cash | 7.0m | 25.9m | (15.5m) | 1.1m | (1.5m) | 10.8m | 8.1m | (2.9m) | |

## Interest Paid | 95.0k | 90.0k | 19.0k | 20.0k | 572.0k | 1.1m | 1.6m | 3.9m | 5.7m |

## Income Taxes Paid | 91.0k | 21.0k | 24.0k | 10.0k | 65.0k | 61.0k | 155.0k | 91.0k |

USD | Y, 2009 |
---|

FY, 2014 | FY, 2015 | FY, 2016 | |
---|---|---|---|

## Patents Issued | 130 | 120 | 100 |

## Patents Pending | 25 | 35 | 30 |

- Source: Company Filings